March 4, 2015
AVAC is pleased to announce a series of three webinars next week, starting on Monday, March 9, that will provide advocates with the chance to hear and discuss data—released last week at the Conference on Retroviruses and Opportunistic Infections (CROI)—in dialogue with researchers and other stakeholders.
These webinars are the first in a year-long series of web-based dialogues focused on HIV prevention research and implementation. This series, HIV Prevention on the Line, will delve into issues raised in our recent AVAC Report and engage with issues and priorities that emerge over the course of the year.
We are also happy to note that this first set of webinars is being produced in partnership with IRMA and the HIV Prevention Justice Alliance. We look forward to working with IRMA and HIV PJA to bring this important information and discussions to a growing audience.
The webinar topics and times are below. Also, please note that the US will change to Daylight Savings Time on Sunday, March 8 so please double check the time in your area at www.timeanddate.com. As always each webinar will be recorded and available online at www.avac.org.
After FACTS: What’s next for HIV prevention in women?
This webinar will feature Helen Rees, principal investigator of the FACTS 001 microbicide trial of vaginal 1% tenofovir gel. FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. What do these and other data mean for women, including young women and adolescent girls? Join the call to share your thoughts and learn more!
Prepare for the webinar with these talks from CROI and excerpts from AVAC Report 2014/15:
- CROI Webcast: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women
- CROI Webcast: Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART
- Excerpts from AVAC Report on microbicides and PrEP
Follow the Money: Knowns and unknowns when it comes to cash transfers and financial incentives to improve health in people living with and/or at risk of HIV
Download slides, audio or view the Flash animation slideshow.
This webinar will feature Wafaa El-Sadr, principal investigator of HPTN 065 which evaluated the use of cash incentives in improving outcomes for people living with HIV in the United States, and David Wilson, the World Bank’s Global AIDS Program Director. Both speakers presented at the recent CROI conference. Cash transfers for young women and girls have also been highlighted in the recent UNAIDS “Fast Track” report and in their draft Prevention Targets released in November 2014. What do the data tell us—and what are the missing pieces? Is now the time to have a cash transfer target—as UNAIDS has proposed—or to articulate an agenda to learn more? Or to do both?
Prepare for the webinar with these talks from CROI and excerpts from AVAC Report 2014/15:
- CROI Webcast: Effect of Financial Incentives on Linkage to Care and Viral Suppression: HPTN 065
- CROI Webcast: Social Protection, Financial Incentives and Prevention of HIV
- Excerpts from AVAC Report on target setting and targets that worked
Demanding Clarity on PrEP: Understanding recent data on oral PrEP
Download slides, audio or view the Flash animation slideshow.
This webinar will feature Jean-Michel Molina of the French research agency ANRS and Sheena McCormack of the UK Medical Research Council to discuss the data from the Ipergay and PROUD studies, respectively. Both trials evaluated oral TDF/FTC (brand name Truvada) as PrEP in gay men and other men who have sex with men, and both reported at CROI, that there were high levels of protection against HIV acquisition. PROUD prescribed a daily pill regimen; IPERGAY asked trial participants to follow an “event driven” regimen that involved a sequence of doses before and after sex. IPERGAY participants took an average of four doses per week—comparable to the estimated protective dose required in trials of daily oral PrEP. So—is there now an “event-driven” regimen? How might these data affecting PrEP delivery and demand in Europe, US and beyond? Join us to explore these conversations—and more!
Prepare for the webinar with these talks from CROI and excerpts from AVAC Report 2014/15:
- CROI Webcast: On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial
- CROI Webcast: Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study
- CROI Plenary Webcast: PrEP for HIV Prevention: What We Know and What We Still Need to Know for Implementation, Raphael Landovitz, University of California Los Angeles
- Excerpt from AVAC Report on PrEP
We look forward to welcoming you on these webinars and others as we move through the year!